News | March 17, 2015

CMS Opens Comment Period for Reconsideration of NaF-18 PET National Coverage Determination Manual

Agency seeking feedback on data collection requirements for use of PET in finding bone cancer metastasis

NOPR, CMS, PET, NaF-18, comment period, bone metastasis

March 17, 2015 — The National Oncologic PET Registry (NOPR) Working Group submitted a formal request to the Centers for Medicare and Medicaid Services (CMS), to end the prospective data collection requirements under Coverage with Evidence Development (CED) for use of NaF-18 PET (CAG-00065R) imaging in intended patient management. CMS has initiated its review of this request.

Positron emission tomography (PET) is a minimally invasive imaging procedure used to assess metabolic activity and perfusion in various organs or tissues. Images are obtained by processing of emissions from positron-emitting radioisotopes that are usually administered intravenously. Sodium fluoride F-18 (NaF-18) is a radioisotope commonly used in oncologic PET imaging procedures to detect bone metastasis in cancer and is the focus of this national coverage analysis.

The rate of NaF-19 uptake provides information on the tissues being studied. NaF-18 PET evaluation can indicate the probable presence or absence of bone metastasis based upon observed differences in biologic activity of adjacent tissues.

Section 220.6.19 of the National Coverage Determination (NCD) Manual establishes the requirement for prospective data collection under CED for NaF-18 PET for bone metastasis in cancer.

At this time, CMS is soliciting comments on the NOPR's request. The public comment period will be open for 30 days, until April 16, 2015. PET facilities participating in the NOPR are encouraged to provide comments (which can be entered directly online on the CMS website at this link). Additionally, PET facilities are encouraged to ask referring physicians who frequently use NaF-18 PET in the care of their patients to submit comments to CMS indicating how NaF-18 PET has helped with patient management. Comments that cite scientific evidence (including unpublished data), including the full range of uses of NaF-18 PET in oncology and the uses of NaF-18 PET in benign bone and joint diseases, will be particularly valuable to CMS.  

For more information: www.cms.gov

Related Content

PET Tracer Identifies Estrogen Receptor Expression Differences in Breast Cancer Patients
News | PET Imaging | August 09, 2018
In metastatic breast cancer, prognosis and treatment is largely influenced by estrogen receptor (ER) expression of the...
Novel PET Imaging Method Could Track and Guide Type 1 Diabetes Therapy
News | PET Imaging | August 03, 2018
Researchers have discovered a new nuclear medicine test that could improve care of patients with type 1 diabetes. The...
Researchers Trace Parkinson’s Damage in the Heart
News | PET Imaging | July 17, 2018
A new way to examine stress and inflammation in the heart will help Parkinson’s researchers test new therapies and...
Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...
SNMMI Image of the Year Highlights Theranostic Approach for Advanced Prostate Cancer

IMAGE OF THE YEAR: PSMA PET before and after lutetium-177 PSMA617 theranostics in 8 patients with metastatic prostate cancer who exhausted standard therapeutic options.

68Ga-PSMA11 PET maximum intensity projection (MIP) images at baseline and 3 months after 177Lu-PSMA617 in 8 patients with PSA decline ≥ 98 percent in a prospective phase II study. Any disease with SUV over 3 is in red. Credit: Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Sue Ping Thang, Price Jackson, Mark Scalzo, Scott Williams and Rodney Hicks, Peter MacCallum Cancer Centre, Melbourne, Australia.

News | PET Imaging | June 29, 2018
In the battle against metastatic castrate-resistant prostate cancer, studies have demonstrated a high response rate to...
MILabs Introduces Futuristic PET Capabilities on New VECTor6 System
Technology | PET Imaging | June 28, 2018
At the 2018 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, June 23-26, in Philadelphia,...
Philips North America and GE Healthcare Win IMV PET Imaging ServiceTrak Awards
News | PET Imaging | June 25, 2018
IMV, part of the Science and Medicine Group and a market research and business intelligence provider to the imaging...
New ASNC SPECT Imaging Guideline Addresses Advances in Myocardial Perfusion Imaging
News | SPECT Imaging | June 21, 2018
The American Society of Nuclear Cardiology (ASNC) has published an update to its 2010 guidelines for single photon...
FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...
Overlay Init